scholarly article | Q13442814 |
P50 | author | Yonglin Pu | Q88757229 |
P2093 | author name string | Haiyan Liu | |
James X Zhang | |||
Daniel Appelbaum | |||
Jianfeng Meng | |||
Bill C Penney | |||
P2860 | cites work | Prognostic Significance of Volume-based Metabolic Parameters by (18)F-FDG PET/CT in Gallbladder Carcinoma | Q33704511 |
Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer | Q33704656 | ||
Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer | Q34977651 | ||
Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. | Q35474006 | ||
Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images | Q35637414 | ||
A new PET/CT volumetric prognostic index for non-small cell lung cancer | Q35688617 | ||
Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. | Q35731341 | ||
Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times | Q36304366 | ||
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. | Q36495076 | ||
What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom | Q37424511 | ||
Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer | Q38014317 | ||
Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines | Q38104633 | ||
Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value | Q38136865 | ||
Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis | Q38246442 | ||
Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey | Q38447643 | ||
Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib | Q38895657 | ||
Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer | Q38925887 | ||
Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer | Q39127172 | ||
Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection | Q43632922 | ||
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. | Q50909685 | ||
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. | Q51005942 | ||
Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. | Q51602164 | ||
Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary? | Q53014495 | ||
FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. | Q53089675 | ||
Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. | Q53140054 | ||
Metabolic tumor burden predicts for disease progression and death in lung cancer. | Q53463840 | ||
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer | Q57272532 | ||
Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer | Q82811825 | ||
Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer | Q83620716 | ||
P433 | issue | 12 | |
P1104 | number of pages | 14 | |
P304 | page(s) | 2079-2092 | |
P577 | publication date | 2018-06-07 | |
P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
P1476 | title | Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging | |
P478 | volume | 45 |
Q92541829 | Development and External Validation of a Nomogram for Predicting Survival in Patients With Stage IA Non-small Cell Lung Cancer ≤2 cm Undergoing Sublobectomy | cites work | P2860 |
Search more.